8-K: Maze Therapeutics Reports Positive Phase 2 MZE829 Data, Strong Cash

Maze Therapeutics announced positive topline Phase 2 data for MZE829 in APOL1-mediated kidney disease, alongside its Q4 and full-year 2025 financial results and a new board appointment.

Summary

• Positive topline data from the Phase 2 HORIZON trial of MZE829 in broad APOL1-mediated kidney disease (AMKD) demonstrated a clinically meaningful mean reduction in proteinuria, as measured by urinary albumin-to-creatinine ratio (uACR), of 35.6% at week 12.
• 50% of broad AMKD patients achieved a greater than 30% reduction in uACR, a threshold strongly correlated with a 10-year delay in progression to end-stage kidney disease.
• In patients with severe focal segmental glomerulosclerosis (FSGS), treatment with MZE829 led to a mean reduction in uACR of 61.8%.
• In patients with AMKD without diabetes, treatment with MZE829 resulted in a clinically meaningful mean reduction in uACR of 48.6%.
• MZE829 was well-tolerated across all doses evaluated, with no serious adverse events or severe treatment-related adverse events observed.
• The company plans to advance MZE829 into a pivotal program based on these results.
• Maze achieved a $20 million milestone payment under its collaboration agreement with Shionogi & Co., Ltd. in connection with the dosing of the first patient in ESPRIT, a global Phase 2 clinical trial evaluating MZE001 in late-onset Pompe disease.
• Neil Kumar, co-founder and Chief Executive Officer of BridgeBio Pharma, Inc., was appointed as a Class I director to the Board of Directors, effective March 27, 2026.
• Cash, cash equivalents, and marketable securities were $360.0 million as of December 31, 2025, with an expected cash runway into 2028.
• Net loss for the fourth quarter ended December 31, 2025, was $34.6 million, compared to a net loss of $29.6 million for the same period in 2024.
• Net loss for the full year ended December 31, 2025, was $131.1 million, compared to a net income of $52.2 million for the full year 2024.
• No license revenue was recognized for the quarter and year ended December 31, 2025, a decrease from $167.5 million in license revenue for the full year 2024.
• Research & Development (R&D) expenses increased to $108.4 million for the full year 2025 from $83.5 million in 2024, primarily due to higher clinical trial and manufacturing expenses for MZE829 and MZE782.
• General & Administrative (G&A) expenses increased to $34.5 million for the full year 2025 from $26.4 million in 2024, primarily due to higher personnel-related expenses.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a highly positive update, driven by strong Phase 2 clinical trial results for MZE829, which significantly de-risks the lead program and provides a clear path to pivotal trials. The robust cash position and strategic board appointment further bolster confidence, despite the reported net loss.

Positives

• Positive topline data from the Phase 2 HORIZON trial of MZE829 in broad AMKD, demonstrating a clinically meaningful mean reduction in proteinuria (uACR) of 35.6% at week 12.
• 50% of broad AMKD patients achieved a greater than 30% reduction in uACR, a threshold strongly correlated with a 10-year delay in progression to end-stage kidney disease.
• MZE829 showed even stronger efficacy in specific subgroups: 61.8% mean uACR reduction in severe FSGS patients and 48.6% in non-diabetic AMKD patients.
• MZE829 was well-tolerated with no serious adverse events or severe treatment-related adverse events.
• Advancement of MZE829 to a pivotal program is planned, indicating significant progress in the lead candidate's development.
• Strong balance sheet with $360.0 million in cash, cash equivalents, and marketable securities as of December 31, 2025.
• Expected cash runway into 2028, providing financial stability for ongoing operations and pipeline development.
• Achieved a $20 million milestone payment from Shionogi & Co., Ltd. for MZE001, with potential for up to $255.0 million in additional clinical/regulatory milestones and up to $330.0 million in sales milestones, plus tiered royalties.
• Appointment of industry leader Neil Kumar to the Board of Directors brings extensive biotechnology executive experience and strategic guidance.

Negatives

• Net loss for the fourth quarter ended December 31, 2025, was $34.6 million, compared to a net loss of $29.6 million for the same period in 2024, indicating increased losses.
• Net loss for the full year ended December 31, 2025, was $131.1 million, a significant shift from a net income of $52.2 million for the full year 2024.
• No license revenue was recognized for the quarter and year ended December 31, 2025, a substantial decrease from $167.5 million in license revenue for the full year 2024.
• Research & Development (R&D) expenses increased to $108.4 million for the full year 2025 from $83.5 million in 2024, reflecting higher operational costs.
• General & Administrative (G&A) expenses increased to $34.5 million for the full year 2025 from $26.4 million in 2024, contributing to increased overall expenses.
• Only two out of five evaluable AMKD patients with diabetes achieved at least a 30% reduction in uACR, indicating less consistent efficacy in this subgroup compared to others.

Risks

• Ability to advance MZE829, MZE782, and other therapeutic candidates.
• Ability to obtain regulatory approval of and ultimately commercialize therapeutic candidates.
• Timing and results of preclinical studies and clinical trials.
• Ability to fund development activities and achieve development goals.
• Ability to protect intellectual property.
• General business and economic conditions.
• Risks related to the impact on business of macroeconomic conditions, including inflation, volatile interest rates, tariffs, instability in the global banking sector, and public health crises.

Future Outlook

The company plans to advance MZE829 into a pivotal program for AMKD and expects to initiate two Phase 2 proof-of-concept trials for MZE782 in PKU by mid-2026 and in CKD in the second half of 2026. The current cash, cash equivalents, and marketable securities are expected to fund operations into 2028.

Management Comments

• Jason Coloma, Ph.D., chief executive officer: "We are proud of the progress that Maze achieved in 2025 and have already carried our strong record of execution into the new year, as evidenced by today's positive topline data from our Phase 2 HORIZON trial of MZE829 in broad AMKD."
• Jason Coloma, Ph.D., chief executive officer: "We look forward to advancing MZE829 into a pivotal program and to initiating our two Phase 2 trials of MZE782 in PKU and CKD."
• Jason Coloma, Ph.D., chief executive officer: "We are also thrilled to announce the addition of Neil Kumar to our Board of Directors. Neil's experience building BridgeBio into the fully-integrated, commercial-stage, patient-centric organization it is today will be invaluable to the team at Maze as we work to grow our company and transform the lives of patients."
• Harold Bernstein, M.D., Ph.D., president of R&D and chief medical officer: "We are pleased to show initial promising proof of concept for MZE829, an oral precision medicine that was designed to treat the underlying cause of AMKD by uniquely inhibiting both pore formation and channel function in the podocyte."
• Harold Bernstein, M.D., Ph.D., president of R&D and chief medical officer: "Based on the data shown today, as well as genetics data derived through our Compass platform, we believe that MZE829's dual mechanism approach has the potential to address the unmet need in AMKD patients."

Industry Context

StockSavvy.ai notes that the positive Phase 2 data for MZE829 in AMKD represents a significant step forward in a disease area with high unmet medical need, potentially affecting over one million people in the U.S. The dual-mechanism approach of MZE829 could offer a differentiated treatment option in the competitive landscape of kidney disease therapies. The advancement of MZE782 into Phase 2 for PKU and CKD also positions Maze in two other areas with substantial patient populations requiring novel treatments. The appointment of Neil Kumar, a seasoned executive from BridgeBio, signals a focus on strategic growth and commercialization expertise, which is crucial for a clinical-stage biopharmaceutical company transitioning towards later-stage development.

Comparison to Industry Standards

• A 30% uACR reduction is widely recognized as a clinically meaningful threshold, strongly correlated with a 10-year delay in progression to end-stage kidney disease. MZE829 achieved a 35.6% mean reduction in broad AMKD patients and 50% of patients achieved greater than 30% reduction, surpassing this benchmark.
• In severe FSGS patients, MZE829 demonstrated a 61.8% mean uACR reduction, which is a robust response compared to general expectations for kidney disease interventions.
• The safety profile of MZE829, with no serious adverse events or severe treatment-related adverse events, is favorable and aligns with expectations for advancing a drug to pivotal trials.
• The $20 million milestone payment from Shionogi for MZE001, with potential for up to $255.0 million in additional clinical and regulatory milestones and up to $330.0 million in sales milestones, reflects a significant validation of the asset's potential by a major pharmaceutical partner, comparable to successful early-stage licensing deals in the biopharma sector.

Management Changes

Corporate Governance

Related Party Transactions

• No family relationships exist among any of the Company's directors or executive officers and Dr. Kumar.
• Dr. Kumar does not have any direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

Stakeholder Impact

• Shareholders: Positive Phase 2 data for MZE829 and a strong cash runway into 2028 could increase investor confidence and potentially lead to share price appreciation. The net loss for 2025, however, indicates continued operational expenses.
• Patients (AMKD, PKU, CKD, Pompe disease): The positive MZE829 data offers hope for a new, effective treatment for AMKD, a disease with high unmet need. Progress on MZE782 and MZE001 also indicates potential future therapies for other serious conditions.
• Employees: Continued progress in clinical development and a strong financial position provide stability and potential for growth within the company.
• Regulatory Authorities: The company plans to engage with regulators to align on a pivotal program for MZE829, indicating a move towards seeking marketing approval.

Next Steps

• Advance MZE829 into a pivotal program for AMKD.
• Continue enrollment in the HORIZON trial for MZE829.
• Initiate Phase 2 proof-of-concept trial for MZE782 in PKU by mid-2026.
• Initiate Phase 2 proof-of-concept trial for MZE782 in CKD in the second half of 2026.
• Meet with regulators and key scientific leaders to align on a pivotal program for MZE829.
• Present HORIZON data at a future medical conference.
• Host a conference call and webcast on March 25, 2026, at 8:00 am EDT to discuss HORIZON data and next steps.

Key Dates

Recommendation

The positive topline Phase 2 data for MZE829 in AMKD, particularly the clinically meaningful reduction in proteinuria and favorable safety profile, represents a significant de-risking event for Maze Therapeutics' lead asset. This data provides a clear path to a pivotal program in a disease with high unmet need. Coupled with a robust cash position extending into 2028, a $20 million milestone achievement for MZE001, and the strategic addition of an experienced industry leader to the board, the company demonstrates strong operational execution and promising pipeline advancement. While the company reported a net loss for 2025, this is typical for a clinical-stage biopharmaceutical company investing heavily in R&D. The overall outlook is highly favorable, suggesting significant upside potential for investors.

Keywords

APOL1-mediated kidney disease, AMKD, MZE829, Phase 2 clinical trial, proteinuria, uACR, focal segmental glomerulosclerosis, FSGS, phenylketonuria, PKU, MZE782, chronic kidney disease, CKD, Pompe disease, MZE001, biopharmaceutical, clinical-stage, precision medicine, BridgeBio Pharma, Neil Kumar, Board of Directors, financial results, cash runway, Shionogi, milestone payment